SANOFI80.BK Sanofi
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- 5.42%
- Fundamental score
- -
Is SANOFI80.BK undervalued?
Graham numberThe Graham number of Sanofi cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sanofi fundamental analysis
No fundamental analysis for Sanofi yet.
Sanofi stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions in Finland and Germany. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection; hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines; and Fluzone, a flu…
Full company profileFinancial statements of Sanofi are not available yet.
Sanofi dividends
Sanofi has not paid dividends in the last 3 fiscal years.
Who owns Sanofi
Ownership data of Sanofi is not available yet.
Sanofi company profile
- Company name
- Sanofi
- Ticker
- SANOFI80.BK
- Exchange
- Thailand Exchange
- Sector
- -
- Industry
- -
- Employees
- 74,846
- Fiscal year end
- December
- Address
- 46, avenue de la Grande ArmEe, Paris, France, 75017
- Phone
- 33 1 53 77 40 00
- Website
- sanofi.com
About Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions in Finland and Germany. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection; hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines; and Fluzone, a flu vaccine. It has a collaboration and license agreement with Exscientia to develop small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab; and antibody collaboration with Regeneron Pharmaceuticals, Inc. to develop antibodies, such as Dupixent (dupilumab) as treatment for diseases driven by type 2 inflammation. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Sanofi management
10- Ms. Belen Garijo Lopez M.D.CEO & Director · born 1960
- Mr. François-Xavier RogerExecutive VP & CFO · born 1962
- Dr. Michael Quigley Ph.D.Chief Scientific Officer & Head of Research
- Mr. Thomas Kudsk LarsenHead of Investor Relations & General Medicines · born 1974
- Ms. Jamie HaneyExecutive VP & General Counsel
- Mr. Pierre ChancelSenior Vice President of Global Diabetes and Senior Vice President of Global Marketing · born 1957
- Ms. Veronique JailletExecutive VP & Interim Chief People Officer
- Fabrizio GaudiHead of Austrian, German & Swiss Operations
- Mr. Erik WallströmHead of Therapeutic Area - Neurology Development
- Mr. Thomas TriompheExecutive Vice President of Vaccines · born 1974